Search Results

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501.

Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders:

Beacon Therapeutics Holdings Limited announced the presentation of 12-month interim safety and efficacy results for the Phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) at the 47th Annual Macula Society Meeting in Palm Springs, California.

Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration provided favorable feedback on the Current Good Manufacturing Practice design of AGTC’s manufacturing facility.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP), at the 45th Macula Society Annual Meeting.

Applied Genetic Technologies Corporation reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa.